Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

27 Apr 2016 10:00

RNS Number : 5000W
Nplus1 Singer Capital Markets Ltd
27 April 2016
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nplus1 Singer Capital Markets Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

Skyepharma Plc

 

(c) Name of the party to the offer with which exempt principal trader is connected:

 

Skyepharma Plc

 

(d) Date dealing undertaken:

26 April 2016

 

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ Sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 100P

 

Purchase

 

28013

 

480p

 

470p

 

ORD 100P

 

Sale

 

6375

 

480p

 

480p

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

Date of disclosure:

27 April 2016

Contact name:

Damian Fernandez

Telephone number:

020 7496 3094

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERKMGZDRNRGVZG
Date   Source Headline
3rd Apr 201411:51 amRNSDirector/PDMR Shareholding
3rd Apr 201411:50 amRNSDirector/PDMR Shareholding
1st Apr 20144:58 pmRNSAnnual Financial Report
31st Mar 20147:45 amRNSProposed Placing and Open Offer to Raise £112m
31st Mar 20147:00 amRNSFinal Results
26th Mar 20147:00 amRNSNotice of Results
6th Mar 20142:44 pmRNSDirector Declaration
5th Mar 20147:00 amRNSBoard Changes
4th Mar 20149:47 amRNSHolding(s) in Company
3rd Mar 20143:38 pmRNSHolding(s) in Company
28th Feb 20147:02 amRNSBoard Change
21st Feb 20142:53 pmRNSAnoro Receives Positive Opinion from CHMP
10th Feb 20145:59 pmRNSHolding(s) in Company
10th Feb 20147:00 amRNSflutiform launched in France
4th Feb 20143:19 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSTrading Update
22nd Jan 20142:50 pmRNSPositive step towards flutiform approval in Spain
19th Dec 20137:45 amRNSANORO ELLIPTA RECEIVES REGULATORY APPROVAL IN US
18th Dec 20132:52 pmRNSUpdate on Lyon manufacturing facility
4th Dec 20137:00 amRNSCapital Markets meeting & flutiform sales update
25th Nov 20135:54 pmRNSDirector/PDMR Shareholding
25th Nov 201310:57 amRNSFurther re Directorate Change
19th Nov 20137:00 amRNSPartner Kyorin launches flutiform in Japan
11th Nov 201311:41 amRNSHolding(s) in Company
11th Nov 201310:42 amRNSDirector/PDMR Shareholding
30th Oct 201311:38 amRNSHolding(s) in Company
10th Oct 20137:00 amRNSInterim Management Statement
24th Sep 20133:39 pmRNSHolding(s) in Company
23rd Sep 20134:31 pmRNSHolding(s) in Company
23rd Sep 20139:31 amRNSHolding(s) in Company
20th Sep 20138:39 amRNSCapital Markets Day, Muttenz, Switzerland
20th Sep 20138:20 amRNSRELVAR ELLIPTA Receives Approval in Japan
20th Sep 20137:00 amRNSflutiform approved in Japan
19th Sep 20132:02 pmRNSHolding(s) in Company
19th Sep 20131:54 pmRNSHolding(s) in Company
19th Sep 20137:00 amRNSflutiform trial for COPD initiated in Europe
22nd Aug 201311:11 amRNSAppointment of Andrew Derodra as CFO
19th Aug 20134:02 pmRNSHolding(s) in Company
15th Aug 20135:20 pmRNSDirector/PDMR Shareholding
15th Aug 20137:00 amRNSHalf Yearly Report
14th Aug 20133:38 pmRNSHolding(s) in Company
1st Aug 20134:08 pmRNSHolding(s) in Company
31st Jul 20139:28 amRNSflutiform recommended for approval in Japan
8th Jul 20137:00 amRNSNotice of Results
20th Jun 201311:00 amRNSflutiform launch in Italy
19th Jun 201312:31 pmRNSHolding(s) in Company
10th Jun 201310:35 amRNSHolding(s) in Company
4th Jun 20134:40 pmRNSSecond Price Monitoring Extn
4th Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 20137:00 amRNSPresenting at Jefferies 2013 Healthcare Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.